<DOC>
	<DOCNO>NCT00004030</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I/II trial study effectiveness VX-853 treating patient solid tumor receive liposomal doxorubicin .</brief_summary>
	<brief_title>VX-853 Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety tolerability VX-853 combination doxorubicin HCl liposome patient relapse incurable solid tumor . II . Obtain pharmacokinetic profile various dosage VX-853 administer combination doxorubicin HCl liposome . III . Achieve whole blood concentration VX-853 predict therapeutically effective range characterize pharmacokinetics dos . IV . Document antitumor effect VX-853 combination doxorubicin HCl liposome patient . OUTLINE : This dose escalation study VX-853 . Patients receive VX-853 orally every 8 hour day 1-3 doxorubicin HCL liposome IV approximately 15 minute begin 26 hour start VX-853 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos VX-853 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : A maximum 45 patient accrue study within approximately 18 month .</detailed_description>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven relapse incurable solid tumor No primary metastatic CNS disease PATIENT CHARACTERISTICS : See General Eligibility Criteria PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 week since prior cytotoxic chemotherapy ( 6 week since prior mitomycin nitrosourea ) Prior doxorubicin HCl allow ( extensive therapy ) Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Prior surgery allow Other : Recovered toxic effect prior therapy At least 4 week since prior investigational approve clinical trial agent No concurrent cimetidine , phenothiazine , phenytoin , calcium channel blocker , cyclosporine Pglycoprotein inhibitors Patients Characteristics Age : 18 Performance Status : Karnofsky 70100 % Life Expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Hemoglobin least 9.0 g/dL Platelet count least 100,000/mm3 Hepatic : AST and/or ALT great 2 time upper limit normal Bilirubin normal Renal : Creatinine normal Creatinine clearance least 60 mL/min Cardiovascular : No clinically significant EKG abnormalities No atrial ventricular arrhythmia require medication No ischemic event within 6 month study Cardiac ejection fraction least 50 % MUGA scan Other : Not pregnant nursing Fertile patient must use effective contraception No prior concurrent seizure disorder No prior concurrent clinically significant medical illness No known hypersensitivity doxorubicin HCl study medication No active malignancy except curatively treat carcinoma situ cervix basal cell skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2001</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>